High density lipoprotein historical perspective: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Overview== ==Historical Perspective== Historically, beginning in the late 1970's cholesterol and lipid assays were promoted ...")
 
No edit summary
Line 11: Line 11:
{{Reflist|2}}
{{Reflist|2}}


{{Lipoproteins}}
{{Lipopedia}}


[[Category:Lipopedia]]
[[Category:Lipid disorders]]
[[Category:Lipid disorders]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Lipoproteins]]
[[Category:Lipoproteins]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 12:23, 13 September 2013

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

High density lipoprotein historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of High density lipoprotein historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on High density lipoprotein historical perspective

CDC on High density lipoprotein historical perspective

High density lipoprotein historical perspective in the news

Blogs on High density lipoprotein historical perspective

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for High density lipoprotein historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Historically, beginning in the late 1970's cholesterol and lipid assays were promoted to estimate total HDL-cholesterol because such tests used to be far less expensive, by about 50 fold, than measured lipoprotein particle concentrations and subclass analysis. Over time, with continued research, decreasing costs, greater availability and wider acceptance of other "lipoprotein subclass analysis" assay methods, including NMR spectroscopy, human studies have continued to show a stronger correlation between human clinically obvious cardiovascular events and quantitatively measured large HDL-particle concentrations.[1]

References

  1. Umemoto T, Han CY, Mitra P; et al. (2013). "Apolipoprotein A-I and HDL Have Anti-Inflammatory Effects onAdipocytes via Cholesterol Transporters: ATP-Binding Cassette (ABC) A-1, ABCG-1 and Scavenger Receptor B-1(SRB-1)". Circulation Research. doi:10.1161/CIRCRESAHA.111.300581. PMID 23501697. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources